Drug Trial Radar · NCT06220201
A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis, Progressive Forms of Multiple Sclerosis or Refractory Myasthenia Gravis (MG) (Breakfree-2)
Last checked: Nov 20, 2026Latest source record: Aug 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
120
Planned (sponsor's estimate)
Start
Mar 28, 2024
Primary completion
Jul 15, 2027
Study completion Jul 15, 2027
Sponsor
- Lead sponsor
- Juno Therapeutics, Inc., a Bristol-Myers Squibb CompanyBristol Myers Squibb (BMY)
- Sponsor type
- Industry
- Collaborators
- Celgene Corporation
- First posted
- Jan 23, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 60 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety, tolerability, efficacy, and drug levels of CC-97540 in participants with Relapsing Forms of Multiple Sclerosis (RMS), Progressive Forms of Multiple Sclerosis (PMS) or Refractory Myasthenia Gravis (MG).
Conditions
- Multiple Sclerosis
- Myasthenia Gravis
Interventions
CC-97540Drug
Specified dose on specified days
FludarabineDrug
Specified dose on specified days
CyclophosphamideDrug
Specified dose on specified days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with adverse events (AEs)Time frame: Up to week 104
- Number of participants with serious adverse events (SAEs)Time frame: Up to week 104
- Number of participants with adverse events of special interest (AESIs)Time frame: Up to week 104
- Number of participants with laboratory test result abnormalitiesTime frame: Up to week 104
- Number of participants with imaging abnormalitiesTime frame: Up to week 104
- Number of participants with dose-limiting toxicities (DLTs)Time frame: Up to week 104
- Recommended Phase 2 dose (RP2D) based on the incidence of DLTs that occur during the DLT evaluation periodTime frame: Up to week 104
Locations
34 sites in 6 countries. Site status is shown where the registry gives one.
Local Institution - 0011
Birmingham, Alabama
University of California, Irvine
Irvine, California
University of Colorado Anschutz Medical Campus
Aurora, Colorado
Colorado Blood Cancer Institute
Denver, Colorado
Yale-New Haven Hospital
North Haven, Connecticut
University of Kansas Medical Center
Kansas City, Kansas
Local Institution - 0005
Boston, Massachusetts
Washington University School of Medicine
St Louis, Missouri
Hackensack University Medical Center
Hackensack, New Jersey
Icahn School of Medicine at Mount Sinai
New York, New York
Neurological Institute of New York
New York, New York
University of Cincinnati Medical Center
Cincinnati, Ohio
Cleveland Clinic Mellen Center
Cleveland, Ohio
Oregon Health and Science University
Portland, Oregon
Swedish Medical Center
Seattle, Washington
Medical College of Wisconsin
Milwaukee, Wisconsin
Antwerp University Hospital
Edegem, Antwerpen, Belgium
UZ Gent
Ghent, Oost-Vlaanderen, Belgium
Hopital Claude Huriez - CHU de Lille
Lille, Nord, France
Pitie Salpetriere University Hospital
Paris, Ville de Paris, France
Local Institution - 0033
Düsseldorf, Germany
Universitaetsklinikum Erlangen
Erlangen, Germany
Klinikum der Universität München Großhadern
München, Germany
Universitaetsklinikum Essen
Essen, North Rhine-Westphalia, Germany
Universitaetsklinikum Magdeburg
Magdeburg, Saxony-Anhalt, Germany
Hospital Universitari i Politecnic La Fe
Valencia, Spain
Hospital Universitari Vall d'Hebron
Barcelona, Barcelona [Barcelona], Spain
Local Institution - 0016
Barcelona, Barcelona [Barcelona], Spain
Hospital Clínic de Barcelona
Barcelona, Catalunya [Cataluña], Spain
Hospital Universitario Ramón y Cajal
Madrid, Madrid, Comunidad de, Spain
Barts Health NHS Trust
London, United Kingdom
Manchester Royal Infirmary
Manchester, Lancashire, United Kingdom
University College London Hospital
London, London, City of, United Kingdom
Salford Royal Hospital
Salford, Manchester, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.